These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 8773364)

  • 1. Response to recombinant human erythropoietin (r-Hu EPO) and L-carnitine combination in patients with anemia of end-stage renal disease.
    Boran M; Dalva I; Gönenç F; Cetin S
    Nephron; 1996; 73(2):314-5. PubMed ID: 8773364
    [No Abstract]   [Full Text] [Related]  

  • 2. L-carnitine and erythropoietin requirements in hemodialysis patients.
    Kavadias D; Fourtounas C; Tsouchnikas J; Barboutis K
    Am J Kidney Dis; 1996 Jul; 28(1):156. PubMed ID: 8712214
    [No Abstract]   [Full Text] [Related]  

  • 3. [Anemia in chronic renal failure. The role of L-carnitine in the treatment of anemia of hemodialyzed patients].
    Wanic-Kossowska M; Kurzawska-Firlej D; Kaźmierski M; Czekalski S
    Pol Arch Med Wewn; 2003 Jan; 109(1):105-11. PubMed ID: 12879773
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of Carnitor for Epogen resistant anemia.
    Simard JC
    ANNA J; 1999 Feb; 26(1):41-2. PubMed ID: 10222857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels.
    Kooistra MP; Struyvenberg A; van Es A
    Nephron; 1991; 57(1):127-8. PubMed ID: 2046808
    [No Abstract]   [Full Text] [Related]  

  • 6. [Combined therapy with L-carnitine and erythropoietin of anemia in chronic kidney failure patients undergoing hemodialysis].
    Wanic-Kossowska M; Kazmierski M; Pawliczak E; Kobelski M
    Pol Arch Med Wewn; 2007; 117(1-2):14-9. PubMed ID: 17642201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
    Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
    BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The importance of erythropoietin in the therapy of anemia in patients on chronic hemodialysis].
    von Appen K; Klinkmann H
    Urol Nefrol (Mosk); 1990; (6):69-70. PubMed ID: 2089771
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
    Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
    Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin.
    Haberl M
    Aust Nurses J; 1990 Sep; 20(2):29. PubMed ID: 2268202
    [No Abstract]   [Full Text] [Related]  

  • 11. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
    Sobota JT
    Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
    [No Abstract]   [Full Text] [Related]  

  • 12. Resistance to recombinant human erythropoietin due to aluminium overload and its reversal by low dose desferrioxamine therapy.
    Yaqoob M; Ahmad R; McClelland P; Shivakumar KA; Sallomi DF; Fahal IH; Roberts NB; Helliwell T
    Postgrad Med J; 1993 Feb; 69(808):124-8. PubMed ID: 8506193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral L-carnitine does not decrease erythropoietin requirement in pediatric dialysis.
    Lilien MR; Duran M; Quak JM; Frankhuisen JJ; Schröder CH
    Pediatr Nephrol; 2000 Nov; 15(1-2):17-20. PubMed ID: 11095004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.
    Binkley LS
    Transplant Proc; 1991 Apr; 23(2):1831-2. PubMed ID: 2053169
    [No Abstract]   [Full Text] [Related]  

  • 15. [Recombinant human erythropoietin and chronic kidney failure: current situation and therapeutic implications].
    Romero González R; Torquet Escuder P
    Med Clin (Barc); 1990 Nov; 95(17):656-9. PubMed ID: 2089205
    [No Abstract]   [Full Text] [Related]  

  • 16. Recombinant human erythropoietin: 18 months' experience in hemodialysis patients.
    Canaud B; Polito-Bouloux C; Garred LJ; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
    Am J Kidney Dis; 1990 Feb; 15(2):169-75. PubMed ID: 2301388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin treatment for anemia in end-stage renal disease with diabetes mellitus.
    Nakatsuka K; Hino M; Miki T; Nishizawa Y; Tabata T; Inoue T; Morii H
    Diabetes Care; 1990 Nov; 13(11):1130-1. PubMed ID: 2261828
    [No Abstract]   [Full Text] [Related]  

  • 18. Does erythropoietin cause epilepsy.
    Cengiz K; Işlek I
    Nephron; 1996; 73(2):320-1. PubMed ID: 8773367
    [No Abstract]   [Full Text] [Related]  

  • 19. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin treatment in children with renal failure.
    Van Damme-Lombaerts R; Herman J
    Pediatr Nephrol; 1999 Feb; 13(2):148-52. PubMed ID: 10229005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.